Kobiolabs, Inc.

Woo Ri Ko

Gwang Pyo Ko

June Chul Lee

In Su Kim

Jin Woo Lee

Hye Jin Kim

Tae-Wook Nam

Hyun Ju You

Tae Wook Nam

Woon Ki Kim

Dae Hee Han

So Yon Yoon

Seok Cheon Song

Hyo In Park

A strain ofKBL697 and the use thereof are described. The strain ofKBL697 (Accession No. KCTC 13520BP) attenuates allergic reactions of cells, significantly improves symptoms of atopic dermatitis, and exhibits anti-inflammatory and anti-fungal effects and a therapeutic effect for intestinal diseases such as irritable bowel syndrome and colitis. Thus, the single strain alone can achieve all the purposes of alleviating allergic diseases and inflammatory diseases and improving intestinal health, thereby finding advantageous applications as a probiotic substance. In addition, the strain, based on the anti-fungal activity thereof, can be advantageously utilized in a skin external preparation against various skin diseases caused by fungi, and in a cosmetic composition and a functional patch for alleviating sensitive skin.

Lactobacillus Gasseri KBL697 strain and use thereof

A strain ofKBL693 and the use thereof are disclosed. The strain ofKBL693 (Accession No. KCTC 13519BP) attenuates allergic reactions of cells, significantly improves symptoms of atopic dermatitis, and exhibits anti-inflammatory and anti-fungal effects. Thus, the single strain alone can achieve all the purposes of alleviating atopic dermatitis and other allergic diseases and improving inflammatory diseases and autoimmune diseases, thereby finding advantageous applications as a probiotic substance. In addition, the strain, based on the anti-fungal activity thereof, can be advantageously utilized in a skin external preparation against various skin diseases caused by fungi, and in a cosmetic composition and a functional patch for alleviating sensitive skin.

Lactobacillus crispatus KBL693 strain and use thereof

KBL697 strain and use thereof

KBL693 strain and use thereof

Growing community of inventors

Seoul, South Korea

Woo Ri Ko